Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells

Oncogenesis

Volumn 5, Issue 10, 2016, Pages

  Vouri, M ^a   Croucher, D R ^b,c,d   Kennedy, S P ^b   An, Q ^a   Pilkington, G J ^a   Hafizi, S ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE B; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL INVASION; CONTROLLED STUDY; DRUG RESISTANCE; FLUORESCENCE; GENE EXPRESSION; GLIOBLASTOMA MULTIFORME CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

EID: 85012853096     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2016.66     Document Type: Article

References (29)

1. Hafizi S, Dahlbäck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006; 17: 295-304.
2. Lemke G. Biology of the TAM Receptors. Cold Spring Harb Perspect Biol 2013; 5: a009076.
3. Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Targeting Axl and Mer Kinases in Cancer. Mol Cancer Ther 2011; 10: 1763-1773.
4. Pierce AM, Keating AK. TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res 2014; 1542: 206-220.
5. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 2001; 293: 306-311.
6. Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK. Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J Immunol 2007; 178: 5635-5642.
7. Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. Academic Press, 2008; 100: 35-83.
8. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial to mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2014; 33: 1316-1324.
9. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107: 1124-1129.
10. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-1448.
11. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-[kappa]B and Brg-1. Oncogene 2008; 27: 4044-4055.
12. Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. Gas6 Anti-apoptotic Signaling Requires NF-κB Activation. J Biol Chem 2001; 276: 31738-31744.
13. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X et al. The tyrosine receptor kinase of Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene 2013; 32: 689-698.
14. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 130-138.
15. Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Oncotarget 2015; 6: 16183-16197.
16. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852-860.
17. Bae SY, Hong J-Y, Lee H-J, Park HJ, Lee SK. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget 2015; 6: 10146-10160.
18. Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triplenegative breast cancer cells. Sci Signal 2013; 6: ra66-ra66.
19. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman C, Luthar N et al. AXL mediates resistance to cetuximab therapy. Cancer Res 2014; 74: 5152-5164.
20. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
21. Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol 2015; 5: 5.
22. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70: 1544-1554.
23. Braunger J, Schleithoff L, Schulz AS, Kessler H, Lammers R, Ullrich A et al. Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is mediated mainly by a multi-substrate docking-site. Oncogene 1997; 14: 2619-2631.
24. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof Raphael A, Brook S et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015; 27: 533-546.
25. Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 2010; 70: 7570-7579.
26. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2. J Biol Chem 1997; 272: 29975-29983.
27. Alqudah MAY, Agarwal S, Al-Keilani MS, Sibenaller ZA, Ryken TC, Assem M. NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR. PLoS ONE 2013; 8: e77299.
28. An Q, Fillmore HL, Vouri M, Pilkington GJ. Brain tumor cell line authentication, an efficient alternative to capillary electrophoresis by using a microfluidicsbased system. Neurooncology 2014; 16: 265-273.
29. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.